PharmX Technologies (ASX:PHX) EBIT : A$0.16 Mil (TTM As of Dec. 2023)

View and export this data going back to 1973. Start your Free Trial

What is PharmX Technologies EBIT?

PharmX Technologies's earnings before interest and taxes (EBIT) for the six months ended in Dec. 2023 was A$0.44 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Dec. 2023 was A$0.16 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. PharmX Technologies's annualized ROC % for the quarter that ended in Dec. 2023 was 1.65%. PharmX Technologies's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was 498.29%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. PharmX Technologies's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was 2.69%.

PharmX Technologies EBIT Historical Data

The historical data trend for PharmX Technologies's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

PharmX Technologies EBIT Chart

PharmX Technologies Annual Data

Trend

Jun14

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

EBIT

Get a 7-Day Free Trial

-0.54

0.51

1.50

0.37

-0.67

PharmX Technologies Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
EBIT	Get a 7-Day Free Trial															0.39	-0.02	-0.39	-0.28	0.44

Competitive Comparison of PharmX Technologies's EBIT

For the Health Information Services subindustry, PharmX Technologies's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

PharmX Technologies's EV-to-EBIT Distribution in the Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, PharmX Technologies's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where PharmX Technologies's EV-to-EBIT falls into.

PharmX Technologies EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was A$0.16 Mil.

PharmX Technologies (ASX:PHX) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

PharmX Technologies's annualized ROC % for the quarter that ended in Dec. 2023 is calculated as:

	ROC % (Q: Dec. 2023 )
=	NOPAT	/	Average Invested Capital
=	Operating Income * ( 1 - Tax Rate % )	/	( (Invested Capital (Q: Jun. 2023 )	+	Invested Capital (Q: Dec. 2023 ))	/ count )
=	0.686 * ( 1 - 41.87% )	/	( (24.766	+	23.677)	/ 2 )
=	0.3987718	/	24.2215
=	1.65 %

where

	Invested Capital		(Q: Jun. 2023 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	36.52	-	1.455	-	( 12.806	-	max(0, 12.29	-	22.589	+	12.806	))
=	24.766

	Invested Capital		(Q: Dec. 2023 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	29.596	-	1.634	-	( 12.44	-	max(0, 11.527	-	15.812	+	12.44	))
=	23.677

Note: The Operating Income data used here is two times the semi-annual (Dec. 2023) data.

2. Joel Greenblatt's definition of Return on Capital:

PharmX Technologies's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2023 is calculated as:

	ROC (Joel Greenblatt) %		(Q: Dec. 2023 )
=	EBIT	/	Average of (Net fixed Assets	+	Net Working Capital)
=	EBIT	/	Average of (Property, Plant and Equipment	+	Net Working Capital)
			Q: Jun. 2023		Q: Dec. 2023
=	EBIT	/	( ( (Property, Plant and Equipment + Net Working Capital)	+	(Property, Plant and Equipment + Net Working Capital) )	/	count )
=	0.872	/	( ( (0.047 + max(-2.506, 0))	+	(0.303 + max(-8.017, 0)) )	/	2 )
=	0.872	/	( ( 0.047	+	0.303 )	/	2 )
=	0.872	/	0.175
=	498.29 %

where Working Capital is:

	Working Capital		(Q: Jun. 2023 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(0.915	+	0	+	8.837)	-	(1.455	+	0	+	10.803)
=	-2.506

	Working Capital		(Q: Dec. 2023 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(2.688	+	0	+	0.72)	-	(1.634	+	0	+	9.791)
=	-8.017

When net working capital is negative, 0 is used.

Note: The EBIT data used here is two times the semi-annual (Dec. 2023) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

PharmX Technologies's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %	=	EBIT (TTM)	/	Enterprise Value (Q: Dec. 2023 )
	=	0.156	/	5.805
	=	2.69 %

PharmX Technologies EBIT Related Terms

Thank you for viewing the detailed overview of PharmX Technologies's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

PharmX Technologies (ASX:PHX) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » PharmX Technologies Ltd (ASX:PHX) » Definitions » EBIT

Comparable Companies

Traded in Other Exchanges

N/A

Address

17 Castlereagh Street, Level 11, Sydney, NSW, AUS, 2000

Website

https://www.corumgroup.com.au

PharmX Technologies Ltd Formerly Corum Group Ltd is an Australia-based software and technology company. The company has a single segment which is Health Services. In Health services, the company develops and distributes business software for the pharmacy industry with particular emphasis on point-of-sale and pharmaceutical dispensing software, support services, and associated computer hardware. It derives a majority of its revenue from the Health services business. the company discontinued the e-commerce business in 2022.